Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02942966




Registration number
NCT02942966
Ethics application status
Date submitted
20/10/2016
Date registered
24/10/2016
Date last updated
31/01/2022

Titles & IDs
Public title
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries
Scientific title
Tack Optimized Balloon Angioplasty Study for the Below The Knee Arteries Using the Tack Endovascular System®
Secondary ID [1] 0 0
CA 0137
Universal Trial Number (UTN)
Trial acronym
TOBA II BTK
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Peripheral Arterial Disease 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Tack Endovascular System

Experimental: Tack Implant - Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections below the knee.


Treatment: Devices: Tack Endovascular System
Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Efficacy - Number of Participants With Freedom From MALE at 6 Months and POD at 30 Days
Timepoint [1] 0 0
6 months
Primary outcome [2] 0 0
Safety - Number of Participants With MALE Plus POD at 30 Days
Timepoint [2] 0 0
30 days
Secondary outcome [1] 0 0
Patency - Number of Target Lesion(s) Tacked Segment(s) Patent at 6 Months
Timepoint [1] 0 0
6 months
Secondary outcome [2] 0 0
Target Limb Salvage - Number of Participants With Freedom From Above-Ankle Target Limb Amputation at 6 Months
Timepoint [2] 0 0
6 months

Eligibility
Key inclusion criteria
* Males or non-pregnant females = 18 years of age at the time of consent
* Female subjects of childbearing potential must have a negative pregnancy test prior to treatment and must use some form of contraception (abstinence is acceptable) through the duration of the study
* Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study. If the subject possesses the ability to understand and provide informed consent but due to physical inability, the subject cannot sign the informed consent form (ICF), an impartial witness may sign on behalf of the subject
* Willing to comply with all required follow-up visits
* Rutherford Classification 4 or 5.
* WIfI Wound grade of 0, 1 or modified 2.
* WIfI Foot Infection grade of 0 or 1.
* Estimated life expectancy =1 year
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Is pregnant or refuses to use contraception through the duration of the study
* Previous bypass graft in the target limb
* Acute limb ischemia, defined as symptom onset occurring less than 14 days prior to the index procedure
* Prior or planned above-ankle amputation or complete transmetatarsal amputation to the target limb (this does not apply to ray amputation of =2 digits, simple digital amputations or ulcer debridements)
* WIfI Foot Infection grade 2 or 3
* Any systemic infection or immunocompromised state. Patients with an ascending infection/deep foot infection or abscess/white blood count (WBC)=12,000/or febrile state
* Endovascular or surgical procedure (not including diagnostic procedures, planned simple digital amputation or wound debridement) to the target limb less than 30 days prior to or planned for less than 30 days after the index procedure
* Existing stent implant in the target vessel
* Any other endovascular or surgical procedure (not including diagnostic procedures, planned simple digital amputation or wound debridement) less than 14 days prior to the index procedure or planned procedure less than 30 days after the index procedure
* Known coagulopathy, hypercoagulable state, bleeding diathesis, other blood disorder, or a platelet count less than 80,000/microliter or greater than 500,000/microliter
* WIfI Wound grade of 2 or 3.
* Any subject in which antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated
* Myocardial infarction, coronary thrombolysis or angina less than 30 days prior to the Index Procedure
* History of stroke or transient ischemic attack (TIA) less than 90 days prior to the Index Procedure
* Currently on dialysis
* Known hypersensitivity or contraindication to nickel-titanium alloy (Nitinol)
* Participating in another ongoing investigational clinical trial in which the subject has not completed the primary endpoint(s)
* Has other comorbidities that, in the opinion of the investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up assessments
* Known hypersensitivity or allergy to contrast agents that cannot be medically managed
* Subject already enrolled into this study
* Restenotic target lesion previously treated by means other than plain balloon angioplasty and/or less than 1 year prior to index procedure.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/02/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/01/2022
Sample size
Target
Accrual to date
Final
233
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New Mexico
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Rhode Island
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Austria
State/province [24] 0 0
Graz
Country [25] 0 0
Czechia
State/province [25] 0 0
Brno
Country [26] 0 0
Germany
State/province [26] 0 0
Arnsberg
Country [27] 0 0
Germany
State/province [27] 0 0
Berlin
Country [28] 0 0
Germany
State/province [28] 0 0
Heide
Country [29] 0 0
Germany
State/province [29] 0 0
Leipzig
Country [30] 0 0
Germany
State/province [30] 0 0
Mülheim an der Ruhr
Country [31] 0 0
Germany
State/province [31] 0 0
Nordheide
Country [32] 0 0
Germany
State/province [32] 0 0
Sonneberg
Country [33] 0 0
Hungary
State/province [33] 0 0
Budapest
Country [34] 0 0
Hungary
State/province [34] 0 0
Kecskemét
Country [35] 0 0
New Zealand
State/province [35] 0 0
Auckland

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Philips Clinical & Medical Affairs Global
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Patrick J. Geraghty, MD
Address 0 0
Washington University School of Medicine in St. Louis
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT02942966